How we exited Carestack — anatomy of a deal

The company

Carestack is the cloud-native practice-management and clinical-platform suite for North American dental practices. The product unifies appointment scheduling, charting, billing, RCM, patient engagement, imaging, and analytics into a single browser-delivered system — replacing the on-premise dental-software stacks that had dominated US practice IT for three decades. It is one of the largest dental-software vendors in North America today, and it is built on a clinical-data foundation engineered in India before the company ever sold a US contract.

Why we backed them, in 2013

We led the angel round in 2013, when Carestack was still pre-revenue and operating out of Cochin. Three things made us lean in.

First, the founders were operators with rare conviction. Abhishek and the team had spent years inside dental services and dental IT, and they understood the buyer's economics — the cost of patient acquisition, the receivables cycle, the staffing leverage of better software — at a level that hypothesis-led founders rarely match. They had been told by sixty-plus investors that India-built dental software for the US market was uninvestable. We disagreed, and we wrote the first check.

Second, the wedge was an Indian-data-native vertical that we believed would compound. North American dental software in 2013 was old, expensive, on-premise, and hated by its users. The cloud rebuild was inevitable. The question was who would build it. Our view was that an India-engineered, US-deployed cloud platform — with the cost structure to invest in clinical depth that incumbents could not match at their unit economics — was the right shape of company to do it.

Third, the moat was data plus distribution. Dental clinical data is geo-locked, regulatory-sensitive, and high-leverage for the AI-enabled features the next generation of practice software would compete on. Whoever built the cleanest data foundation first, with the trust to win US group-practice deployments, would have a moat that compounded with every additional clinic on the platform.

What we did beyond the check

The angel position was small, but the post-check work was outsized.

We brought Accel into the Series A as the lead investor. The introduction, the diligence support, and the round structuring were ours — and Accel's lead validated the company at a stage when most US institutional capital was still skeptical of India-engineered SaaS for the US enterprise. Carestack went on to raise more than $145 million across subsequent rounds, including substantial growth-stage capital.

We worked the US go-to-market. The transition from Cochin-headquartered company to credible North-American dental-software vendor required intentional repositioning — US advisory hires, US-led customer success, a sales motion built around dental DSO buyers rather than independent practitioners. We supported each of those threads.

We held the position through the long arc. Eight-plus years from first check to full exit is not the modal angel outcome; most angel positions are either marked-up paper or zeros. Holding through dilution, follow-on cycles, and product pivots requires conviction, and the conviction came from the original thesis still being correct.

The exit, and what it proved

We exited the position fully in April 2021, when Carestack closed its growth round. The realized return on the angel position was the headline win on the Callapina ledger — eight years from first check, with the company by then on a path that has subsequently raised over $145 million in additional capital. The per-dollar IRR is what underwrites our 3.15× realized angel MOIC at approximately 30% IRR across the broader angel book.

More important than the dollar return is what the deal proved. The four-pillar thesis we publish today was, in 2013, untested. Carestack tested it: an Indian-origin founder, an Indian-data-native vertical, a North American go-to-market, an early check from a corridor-focused investor, and a tier-1 follow-on lead brought in by that investor. Every piece of the playbook we now run for Fund II ran first inside Carestack — the sourcing, the conviction-pricing, the Accel introduction, the cross-border operating support, the long hold.

The same shape is visible in every Fund I bet today. Bynry, Runo, Whatmore, DeepIQ, Sastra Robotics — each one is, in its own segment, an iteration on the pattern Carestack proved was investable.

The full circle

Two of the founders we exited with on the angel ledger have since come back as LPs in Callapina. The relationship does not end at the wire transfer. The discipline that produced the outcome on one side compounds into capital commitment on the other. That feedback loop — exited founders putting their realized capital back into the next fund — is the receipt that the GP-founder relationship was real, not transactional.

The Callapina conviction

We back founders we would back again. Carestack is the angel that became the institutional fund, and the discipline we learned from holding it for eight years is the discipline we will apply to Fund II's positions over the next decade. The exit closed one chapter; the playbook compounds into the next.

— Vinod Jose, Founding GP